Table 3.
Univariable and multivariable analysis with respect to disease-free survival in breast cancer subtypes
| Univariable analysis | Multivariable analysis | ||||||
|---|---|---|---|---|---|---|---|
| Parameter | Hazard ratio | 95% c.i. | p value | Hazard ratio | 95% c.i. | p value | |
| All breast cancers (n = 177) | |||||||
| Age | ≤56 vs >56 | 0.809 | 0.395–1.657 | 0.561 | |||
| Menopause | Pre- vs Post- | 0.840 | 0.408–1.731 | 0.637 | |||
| Tumor size (cm) | ≤2 vs >2 | 1.062 | 0.370–3.045 | 0.911 | |||
| Lymph node status | Negative vs Positive | 4.157 | 0.990–17.456 | 0.052 | |||
| Nuclear grade | 1–2 vs 3 | 1.025 | 0.440–2.389 | 0.954 | |||
| Ki67 (%) | ≤14 vs >14 | 0.649 | 0.316–1.331 | 0.238 | |||
| Intrinsic subtype | TNBC vs non-TNBC | 1.213 | 0.577–2.550 | 0.611 | |||
| Intrinsic subtype | HER2BC vs non- HER2BC | 0.695 | 0.266–1.818 | 0.459 | |||
| Intrinsic subtype | HRBC vs non-HRBC | 1.054 | 0.514–2.160 | 0.886 | |||
| Pathological response | pCR vs non-pCR | 0.611 | 0.279–1.336 | 0.217 | 1.008 | 0.402–2.524 | 0.987 |
| TILs | High vs Low | 0.420 | 0.199–0.885 | 0.022 | 4.785 | 1.169–19.582 | 0.029 |
| RCB-TILs | Positive vs Negative | 0.181 | 0.082–0.401 | <0.001 | 0.048 | 0.012–0.188 | <0.001 |
| TNBC (n = 61) | |||||||
| Age | ≤56 vs >56 | 0.690 | 0.211–2.262 | 0.541 | |||
| Menopause | Pre- vs Post- | 0.652 | 0.199–2.136 | 0.480 | |||
| Tumor size (cm) | ≤2 vs >2 | 0.550 | 0.119–2.546 | 0.444 | |||
| Lymph node status | Negative vs Positive | 0.942 | 0.203–4.359 | 0.939 | |||
| Nuclear grade | 1–2 vs 3 | 1.553 | 0.455–5.307 | 0.482 | |||
| Ki67 (%) | ≤14 vs >14 | 0.739 | 0.216–2.526 | 0.630 | |||
| Pathological response | pCR vs non-pCR | 0.234 | 0.050–1.084 | 0.063 | 0.270 | 0.030–2.466 | 0.246 |
| TILs | High vs Low | 0.177 | 0.054–0.583 | 0.004 | 0.243 | 0.071–0.816 | 0.023 |
| RCB-TILs | Positive vs Negative | 0.099 | 0.029–0.343 | <0.001 | 0.041 | 0.003–0.573 | 0.018 |
| HER2BC (n = 36) | |||||||
| Age | ≤56 vs >56 | 1.245 | 0.207–7.493 | 0.811 | |||
| Menopause | Pre- vs Post- | 2.507 | 0.280–22.443 | 0.411 | |||
| Tumor size (cm) | ≤2 vs >2 | 0.693 | 0.081–6.302 | 0.744 | |||
| Lymph node status | Negative vs Positive | 3.732 | 0.072–5.051 | 0.414 | |||
| Nuclear grade | 1–2 vs 3 | 0.043 | 0.011–5.216 | 0.513 | |||
| Ki67 (%) | ≤14 vs >14 | 0.441 | 0.068–2.623 | 0.364 | |||
| Pathological response | pCR vs non-pCR | 0.482 | 0.078–2.847 | 0.415 | 0.702 | 0.108–4.551 | 0.710 |
| TILs | High vs Low | 0.123 | 0.020–0.774 | 0.026 | 0.134 | 0.020–0.879 | 0.036 |
| RCB-TILs | Positive vs Negative | 0.123 | 0.020–0.774 | 0.026 | 0.134 | 0.020–0.879 | 0.036 |
| HRBC (n = 80) | |||||||
| Age | ≤56 vs >56 | 0.856 | 0.297–2.467 | 0.773 | |||
| Menopause | Pre- vs Post- | 0.769 | 0.270–2.193 | 0.623 | |||
| Tumor size (cm) | ≤2 vs >2 | 2.462 | 0.322–18.836 | 0.386 | |||
| Lymph node status | Negative vs Positive | 3.682 | 0.151–10.382 | 0.205 | |||
| Nuclear grade | 1–2 vs 3 | 1.063 | 0.303–3.811 | 0.930 | |||
| Ki67 (%) | ≤14 vs >14 | 0.602 | 0.212–1.738 | 0.344 | |||
| Pathological response | pCR vs non-pCR | 1.328 | 0.438–3.973 | 0.614 | 2.123 | 0.667–6.750 | 0.202 |
| TILs | High vs Low | 0.992 | 0.311–3.165 | 0.990 | 1.044 | 0.323–3.372 | 0.949 |
| RCB-TILs | Positive vs Negative | 0.258 | 0.071–0.932 | 0.039 | 0.081 | 0.016–0.409 | 0.002 |
c.i confidence interval, TILs tumor-infiltrating lymphocytes, RCB residual cancer burden, TNBC triple-negative breast cancer, HER2BC human epidermal growth factor receptor 2-enriched breast cancer, HRBC hormone receptor-positive breast cancer, pCR pathological complete response